1. Show article details.

    Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls

    Business Wire – 7:00 AM ET 09/21/2021

    Index Finds Women’s Health Needs Are Not Being Met Globally and Provides Data Roadmap for Improvement Analysis Identifies Five Health Dimensions that Correlate with Women’s Life Expectancy Hologic, Inc. (HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s he...

  2. Show article details.

    Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

    Business Wire – 4:04 PM ET 09/02/2021

    Hologic, Inc. (HOLX) announced today that the Company will present at these upcoming virtual investor conferences: Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following the events.

  3. Show article details.

    Anthem, Nation’s Second Largest Health Plan, Now Covers Hologic’s Acessa Procedure as a Treatment for Uterine Fibroids

    Business Wire – 8:05 AM ET 08/23/2021

    Coverage Further Validates Laparoscopic Radiofrequency Ablation for Women with Uterine Fibroids Hologic, Inc. (HOLX), a global leader in women’s health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United States, has updated its medical policy to cover Radiofrequency Ablation, which includes the Acessa® procedure, for women suffering from uterine fibroids.

  4. Show article details.

    The Surge in New Cases Reinforces the Importance of a Healthy Lifestyle

    PR Newswire – 9:00 AM ET 08/09/2021

    NEW YORK, Aug. 9, 2021 While most of the economy has reopened, the number of new cases is once again on the rise. As a result, the highly transmissible delta variant now accounts for 83% of all positive samples. in New York City. As of last Friday, all five boroughs of the city have met the CDC guidelines to be considered "high transmission" areas where extra precautions should be taken.

  5. Show article details.

    BRIEF-Hologic Announces Q3 Revenue $1.168 bln

    Reuters – 4:10 PM ET 07/28/2021

    Hologic Inc (HOLX): * HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL 2021. * Q3 REVENUE $1.168 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.04 BILLION. * Q3 NON-GAAP EARNINGS PER SHARE $1.33. * Q3 GAAP EARNINGS PER SHARE $1.04. * Q3 EARNINGS PER SHARE ESTIMATE $1.12 -- REFINITIV IBES DATA. * SEES Q4 REVENUE $1,000 MILLION - $1,040 MILLION.

  6. Show article details.

    Hologic Announces Financial Results for Third Quarter of Fiscal 2021

    Business Wire – 4:01 PM ET 07/28/2021

    — Revenue of $1.168 Billion Increases 42.0%, 37.8% in Constant Currency —. — Organic Revenue Increases 38.4%, 34.2% in Constant Currency —. — Company Posts GAAP Diluted EPS of $1.04, Non-GAAP Diluted EPS of $1.33 —. Hologic, Inc. (HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 26, 2021.

  7. Show article details.

    New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium

    Business Wire – 8:02 AM ET 07/26/2021

    With STIs reaching a new high for the sixth consecutive year, a more inclusive screening approach is considered for chlamydia and gonorrhea in women under 25 First CDC guidelines to recommend testing specific populations for Mycoplasma genitalium, which was previously listed as an emerging issue MARLBOROUGH, Mass.

  8. Show article details.

    Latest Spike in Cases Reiterates the Importance of Comprehensive Diagnostics

    PR Newswire – 9:00 AM ET 07/20/2021

    NEW YORK, July 20, 2021 Concerns over the pandemic are once again in the forefront as the Delta strain has become the driving force of new COVID surge. Even though vaccines are available and are being rolled out, testing remains a crucial factor.

  9. Show article details.

    BRIEF-Hologic Obtains European CE Mark For Use Of Saliva Samples With COVID-19 Test

    Reuters – 2:02 AM ET 07/14/2021

    Hologic Inc (HOLX): * HOLOGIC OBTAINS EUROPEAN CE MARK FOR USE OF SALIVA SAMPLES WITH COVID-19 TEST Source text for Eikon: Further company coverage:

  10. Show article details.

    Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

    Business Wire – 2:00 AM ET 07/14/2021

    Hologic, Inc. (HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima® SARS-CoV-2 assay in Europe. “This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic,” said Jan Verstreken, Hologic’s group president, International. Collection of saliva is easy, noninvasive and painless.

  11. Show article details.

    Hologic to Announce Financial Results for the Third Quarter of Fiscal 2021 on Wednesday, July 28, 2021

    Business Wire – 8:15 AM ET 07/06/2021

    Hologic, Inc. (HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2021 on Wednesday, July 28, after the market closes. Interested participants may listen to the call by dialing 888-204-4368 or +1 323-994-2093 and referencing access code 5101679.

Page:

Today's and Upcoming Events

  • Nov
    02

    HOLX to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jul
    28

    HOLX announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.